Adaptin Bio (APTN) EPS (Weighted Average and Diluted) (2023 - 2026)

Adaptin Bio has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting $0.13 for Q1 2026.

• Quarterly EPS (Weighted Average and Diluted) rose 30.0% year-over-year to $0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.41 (up 45.33% YoY) and the FY2025 annual result came in at -$0.66, up 31.25% from the prior year.
• EPS (Weighted Average and Diluted) advanced to $0.13 in Q1 2026, from -$0.16 in the prior quarter.
• Across five years, EPS (Weighted Average and Diluted) topped out at $0.13 in Q1 2026 and bottomed at -$0.34 in Q3 2024.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.1 (2024), against an average of -$0.1.
• Year-over-year, EPS (Weighted Average and Diluted) slumped 24900.0% in 2024 and surged 200.0% in 2025.
• Adaptin Bio's EPS (Weighted Average and Diluted) stood at -$0.01 in 2023, then tumbled by 3614.29% to -$0.26 in 2024, then jumped by 38.46% to -$0.16 in 2025, then soared by 181.25% to $0.13 in 2026.
• According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $0.13, -$0.16, and -$0.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.